CELL BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,000 KRW | -0.08% |
|
-0.83% | +6.95% |
| Sales 2022 | 50.53B 37.14M | Sales 2023 | 53.79B 39.53M | Capitalization | 76.79B 56.44M |
|---|---|---|---|---|---|
| Net income 2022 | 8.28B 6.09M | Net income 2023 | 6.3B 4.63M | EV / Sales 2022 | 0.45 x |
| Net cash position 2022 | 64.41B 47.34M | Net cash position 2023 | 68.78B 50.55M | EV / Sales 2023 | 0.15 x |
| P/E ratio 2022 |
10.6
x | P/E ratio 2023 |
12.2
x | Employees | 122 |
| Yield 2022 |
3.54% | Yield 2023 |
4.01% | Free-Float | 47.72% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.08% | ||
| 1 week | -0.83% | ||
| 1 month | -0.25% | ||
| 3 months | -4.08% | ||
| 6 months | +10.09% | ||
| Current year | +6.95% |
1 week
11 850.00
12 410.00
1 month
11 800.0012 890.00
Current year
11 050.0013 630.00
1 year
10 500.0014 320.00
3 years
10 300.0021 250.00
5 years
10 050.0026 350.00
10 years
10 050.0073 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 22-03-29 | |
Young-Ok Yoon
BRD | Director/Board Member | 61 | - |
Seong-Bae Yoon
BRD | Director/Board Member | 59 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 22-03-29 | |
Seong-Bae Yoon
BRD | Director/Board Member | 59 | - |
Young-Ok Yoon
BRD | Director/Board Member | 61 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 12,000 | -0.08% | 12 527 |
| 24-05-27 | 12,010 | -2.91% | 23,644 |
| 24-05-24 | 12,370 | +0.08% | 12,776 |
| 24-05-23 | 12,360 | +0.65% | 38,521 |
| 24-05-22 | 12,280 | -0.81% | 10,951 |
End-of-day quote Korea S.E., May 27, 2024
More quotes
CELLBIOTECH Co., Ltd is a Korea-based company engaged in the manufacturing of bio products. The Company's products include lactic acid bacteria (LAB) powders and finished products containing LABs. Its LAB powders are used as raw materials in foods and medicines for the functions of immunization enhancement and digestion improvement. Its finished products containing LABs are used for intestinal health improvement, carcinogen inhibition, calcium supplement and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +6.95% | 60.42M | |
| +9.82% | 118B | |
| +9.90% | 106B | |
| -11.09% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.67% | 15.97B | |
| +6.80% | 14.03B | |
| +16.15% | 11.67B |
- Stock Market
- Equities
- A049960 Stock
